Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20089 vs investigator-choice chemotherapy in platinum-resistant recurrent epithelial ovarian cancer
CTR20250629Phase 3Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mocertatug rezetecan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hansoh Pharmaceutical Group. Started Mar 2025; status: active.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20250629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250629.